Non-opioid analgesics have broad applications in treating mild or severe pain, including pain associated with musculoskeletal, surgical, trauma, cancer, or other types of pain.
Non-opioid analgesics have broad applications in treating mild or severe pain, including pain associated with musculoskeletal, surgical, trauma, cancer, or other types of pain. In the last decade, the innovation in the market has been more likely limited to new extended-release formulations and new drug delivery systems. The advancements in delivery systems and new treatments offer improvements in symptom relief. However, effective analgesics with a low risk of intolerance and abuse are still a major unmet need in the market.
Rising restrictions on opioid-based products create lucrative opportunities for the non-opioid drug market. Opioid abuse and addiction, which includes prescription medications & drugs like fentanyl and heroin, is a critical global problem that negatively impacts public health and economic & social wellbeing. In the U.S., approximately 50,000 deaths occurred from opioid-related overdoses in 2021. In addition, according to data from Medicare, in the last decade, opioid prescriptions from oncologists declined by 21% and 23% from other doctors. Similarly, according to the report published by National Cancer Institute in 2021, the same trend had been observed among last-stage cancer patients. This trend is expected to continue during the forecast period, which has created a massive opportunity for space growth.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39482
Analgesic drugs class has been mainly segmented as:
- NSAIDs
- Acetaminophen
- Local Anesthetics
Investment in R&D has led to the development of novel therapeutic options that are highly effective, with lesser side effects. NSAIDs include a group of drugs used in pain, fever, and inflammation due to their analgesic, antipyretic, & anti-inflammatory properties. The space is strategically active with the approval of novel drugs. For instance, Heron Pharma’s ZYNRELEF, an extended-release dual-acting local anesthetic used as a single needle-free application, was approved by the U.S. FDA in May 2021. It is a unique drug for postoperative pain management associated with cancers and other surgeries. It is an essential milestone in ongoing efforts to get ahead of the opioid crisis in the U.S. with preventative measures. Nonetheless, the need for developing a non-opioid-based treatment approach is high, and there remains optimism for developing a novel therapy to treat pain.
Among pain types, neuropathic pain is anticipated to exhibit remunerative growth in the forthcoming years; this is more likely due to the robust product pipeline with major products in Phase II and Phase III development.
Owing to the uncertain opioid regulatory situation, pharma giants are shifting their focus on non-opioid analgesics, companies such as The WIRB-Copernicus Group’s (WCG) acquired Analgesic Solutions, LLC. Major companies operating in the space include AbbVie Inc.; Pfizer, Inc, Lilly; Teva Pharmaceutical Industries Ltd., Viatris Inc., Centrexion Therapeutics, Cara Therapeutics, Medropharm GmbH.
Market Segmentation
- By Drug Class
- NSAIDs
- Acetaminophen
- Local Anesthetics
- By Pain Type
- Post-operative Pain
- Cancer Pain
- Neuropathic Pain
- Others
- By Route Of Administration
- Oral
- Topical
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39482
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333